Unlocking the Potential of C1orf216: A Promising Drug Target and Biomarker

Target Name: C1orf216

NCBI ID: G127703

C1orf216

Other Name(s): UPF0500 protein C1orf216 | C1orf216 variant 1 | CA216_HUMAN | Chromosome 1 open reading frame 216, transcript variant 1 | chromosome 1 open reading frame 216

Unlocking the Potential of C1orf216: A Promising Drug Target and Biomarker

Introduction

C1orf216 is a protein located in the nucleoplasm of human cells, which has been identified as a potential drug target and biomarker. Its unique structure and various functions make it an attractive target for drug development, as it can modulate various cellular processes, including cell adhesion , migration, and angiogenesis. This article will explore the biology of C1orf216, its potential drug targets, and its potential as a biomarker for various diseases.

Structure and Functions of C1orf216

C1orf216 is a 216-kDa protein that is located in the nucleoplasm of human cells. It belongs to the TATA-repeat transcription factor A (TATA-repeat) family, which is known for their role in gene regulation and DNA binding. C1orf216 is composed of a unique N-terminal domain, a TATA-repeat domain, a protein-coding domain, and a C-terminal domain.

The N-terminal domain of C1orf216 contains a short cytoplasmic domain that is involved in protein-protein interactions and may play a role in regulating the localization and stability of the protein. The TATA-repeat domain, which is the largest part of the protein, is responsible for DNA binding and is known for its role in gene regulation. The protein-coding domain contains the coding sequence for the protein, which has not yet been fully identified. Finally, the C-terminal domain is a unique feature that is specific to C1orf216 and may be involved in its stability or localization.

Potential Drug Targets

C1orf216 has been identified as a potential drug target due to its unique structure and various functions. One of the most promising targets is the protein p53, which is a well-known tumor suppressor protein that plays a critical role in regulating cell growth and apoptosis.

The p53 protein is a transmembrane protein that is composed of a N-terminal domain, a TATA-repeat domain, a protein-coding domain, and a C-terminal domain. It has various functions in cell regulation, including transcription, RNA binding, DNA binding, cell cycle regulation, apoptosis regulation, cell proliferation regulation, etc.

C1orf216 has been shown to interact with p53 and can modulate its activity. This interaction between C1orf216 and p53 suggests that C1orf216 may be a useful drug target for cancer treatment.

In addition to its potential interaction with p53, C1orf216 has also been shown to interact with other proteins, including retinoic acid receptor (RXR) and transcription factor binding protein (TBP). These interactions further demonstrate the potential role of C1orf216 in drug screening and treatment of cancer.

Potential Biomarkers

C1orf216 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

1. Cancer: C1orf216 has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to be involved in the regulation of cell cycle, apoptosis, and angiogenesis, which are all critical processes that are often disrupted in cancer cells. Therefore, C1orf216 may be a useful biomarker for cancer diagnosis, prognosis, and treatment.

2. Neurodegenerative Diseases: C1orf216 has been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It has been shown to interact with various proteins that are involved in neurodegeneration, including beta-amyloid (尾-amyloid) and 纬-secretase (纬-secretase). Therefore, C1orf216 may serve as a candidate for these diseases

Protein Name: Chromosome 1 Open Reading Frame 216

The "C1orf216 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C1orf216 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets